Your browser doesn't support javascript.
loading
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton, Lindsay; Taylor, Matthew; Soonasra, Arif; Bourret, Jeffrey A; Gerber, Robert A.
Affiliation
  • Claxton L; 1 York Health Economics Consortium, University of York, United Kingdom.
  • Taylor M; 1 York Health Economics Consortium, University of York, United Kingdom.
  • Soonasra A; 2 Pfizer, Collegeville, Pennsylvania.
  • Bourret JA; 2 Pfizer, Collegeville, Pennsylvania.
  • Gerber RA; 3 Pfizer, Groton, Connecticut.
J Manag Care Spec Pharm ; 24(10): 1010-1017, 2018 Oct.
Article in En | MEDLINE | ID: mdl-29897007

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Arthritis, Rheumatoid / Pyrimidines / Pyrroles / Biological Products / Methotrexate / Tumor Necrosis Factor-alpha / Drug Costs / Antirheumatic Agents / Protein Kinase Inhibitors Type of study: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Manag Care Spec Pharm Year: 2018 Document type: Article Affiliation country: United kingdom Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Arthritis, Rheumatoid / Pyrimidines / Pyrroles / Biological Products / Methotrexate / Tumor Necrosis Factor-alpha / Drug Costs / Antirheumatic Agents / Protein Kinase Inhibitors Type of study: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Manag Care Spec Pharm Year: 2018 Document type: Article Affiliation country: United kingdom Country of publication: United States